Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series

Peter Theut Riis, Jurr Boer, Errol P. Prens, Ditte M.L. Saunte, Inge E. Deckers, Lennart Emtestam, Karin Sartorius, Gregor B.E. Jemec

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


Background Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence. Objective We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS. Methods This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted. Results Significant reductions in physician-assessed erythema (median score from 2-1, P < .0001), edema (median score from 2-1, P < .0001), suppuration (median score from 2-1, P < .0001), and size (median score from 3-1, P < .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P < .005) and from day 1 to day 2 (from 2.3-1.4, P < .002). Limitations Small study size, open single-arm design, and short follow-up time are the limitations of this study. Conclusion Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.

Sider (fra-til)1151-1155
Antal sider5
TidsskriftJournal of the American Academy of Dermatology
Udgave nummer6
StatusUdgivet - 1 dec. 2016


Udforsk hvilke forskningsemner 'Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series' indeholder.